m6223
mAbexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 10, 2020 (NCT04457778)
Timeline
Indications
Mechanism of action
TIGIT inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05327530 | Phase 2 | Aug 17, 2022 | Merck, Merck KGaA, Merck Serono |
| NCT04457778 | Phase 1 | Jul 10, 2020 | Merck KGaA, Merck Serono |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck KGaA | For profit | 2 | 0 | 2 | 2020 |
| Merck Serono | For profit | 2 | 2 | 2 | 2020 |
| Merck | For profit | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1